Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients : a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)
BACKGROUND: Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available.
METHODS: The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study.
DISCUSSION: This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System.
TRIAL REGISTRATION: ClincalTrials.gov NCT04147026 . Registered on 31 October, 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Trials - 21(2020), 1 vom: 31. Aug., Seite 755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Freites-Núñez, Dalifer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-TNFα agents |
|---|
| Anmerkungen: |
Date Completed 17.06.2021 Date Revised 29.03.2024 published: Electronic ClinicalTrials.gov: NCT04147026 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13063-020-04683-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314409386 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314409386 | ||
| 003 | DE-627 | ||
| 005 | 20240329234725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-020-04683-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM314409386 | ||
| 035 | |a (NLM)32867830 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Freites-Núñez, Dalifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients |b a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2021 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04147026 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available | ||
| 520 | |a METHODS: The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study | ||
| 520 | |a DISCUSSION: This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System | ||
| 520 | |a TRIAL REGISTRATION: ClincalTrials.gov NCT04147026 . Registered on 31 October, 2019 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-TNFα agents | |
| 650 | 4 | |a Personalized medicine | |
| 650 | 4 | |a Prediction models | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 700 | 1 | |a Baillet, Athan |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Rodriguez, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Minh Vu Chuong |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Isidoro |e verfasserin |4 aut | |
| 700 | 1 | |a Pablos, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Balsa, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Vazquez, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Gaudin, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Gutierrez, Benjamín |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d 2006 |g 21(2020), 1 vom: 31. Aug., Seite 755 |w (DE-627)NLM161320430 |x 1745-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:31 |g month:08 |g pages:755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-020-04683-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 1 |b 31 |c 08 |h 755 | ||